{
    "clinical_study": {
        "@rank": "151355", 
        "arm_group": [
            {
                "arm_group_label": "Resection", 
                "arm_group_type": "Experimental", 
                "description": "To observe prognosis of resection of icc"
            }, 
            {
                "arm_group_label": "Radiotherapy", 
                "arm_group_type": "Active Comparator", 
                "description": "To observe the prognosis of radiotherapy treatment of icc"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to confirm that prognosis of Intrahepatic Cholangiocarcinoma\n      (ICC) with resection and radiotherapy ,to find which is safe and effective treatment."
        }, 
        "brief_title": "Prognosis of Resection and Radiotherapy in the Treatment of Intrahepatic Cholangiocarcinoma Patients", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Intrahepatic Cholangiocarcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Cholangiocarcinoma", 
                "Liver Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Intrahepatic Cholangiocarcinoma (ICC), the second most common primary liver cancer and\n      constitutes 10% of primary liver malignancies.\n\n      Current therapies for the treatment of ICC are ineffective and the role of liver\n      transplantation is not well defined.\n\n      This study reviews our experience with this tumor and looks for preoperative and pathologic\n      indices that may help determine long term prognosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female patients > 17 years and <=60 years of age. confirmed case (patients\n             with ICC) Tumors can be radical removed and resection volume was \u226450%. Criteria of\n             liver function: Child A level, serum bilirubin \u2264 1.5 times the upper limit of normal\n             value,alanine aminotransferase and aspartate aminotransferase \u2264 2 times the upper\n             limit of normal value.\n\n        No dysfunction in major organs; Blood routine, kidney function, cardiac function and lung\n        function are basically normal. Hbg \u2265 90g/L, WBC \u2265 3.000 cells/mm\u00b3,platelets \u2265 80.000\n        cells/mm\u00b3.\n\n        Karnofsky Performance Score performance over 60. Patients who can understand this trial\n        and have signed information consent.\n\n        Exclusion Criteria:\n\n          -  Patients who have undergone previous treatment by Resection or Radiotherapy. Patients\n             with apparent cardiac, pulmonary, cerebronic and renal dysfunction, which may affect\n             the treatment of liver cancer.\n\n        Patients with other diseases which may affect the treatment mentioned here. Patients with\n        medical history of other malignant tumors. Subjects participating in other clinical\n        trials. Extrahepatic metastasis, portal vein or other major vascular involvement. liver\n        function: Child B C.\n\n        Patients would not sign the consent to the trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "17 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01914289", 
            "org_study_id": "EHBH-RCT-2013-002-02"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Resection", 
                    "Radiotherapy"
                ], 
                "intervention_name": "Resection", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": [
                    "Resection", 
                    "Radiotherapy"
                ], 
                "intervention_name": "Radiotherapy", 
                "intervention_type": "Radiation"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Intrahepatic Cholangiocarcinoma", 
            "Prognosis", 
            "Resection", 
            "Radiotherapy"
        ], 
        "lastchanged_date": "August 1, 2013", 
        "location": {
            "contact": {
                "email": "ajli62@gmail.com", 
                "last_name": "Li Aijun, MD", 
                "phone": "86-21-81875531"
            }, 
            "contact_backup": {
                "email": "yuanhang8106@163.com", 
                "last_name": "Yuan Hang, doctor", 
                "phone": "86-21-81875531"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200438"
                }, 
                "name": "Eastern Hepatobiliary Surgery Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Comparison of Resection and Radiotherapy in the Prognosis of Intrahepatic Cholangiocarcinoma Patients", 
        "overall_contact": {
            "email": "ajli62@gmail.com", 
            "last_name": "Li Aijun, MD", 
            "phone": "86-21-81875531"
        }, 
        "overall_contact_backup": {
            "email": "yuanhang8106@163.com", 
            "last_name": "Yuan Hang", 
            "phone": "86-21-81875531"
        }, 
        "overall_official": {
            "affiliation": "Eastern Hepatobiliary Surgery Hospital, Second Military Medical University", 
            "last_name": "Li Aijun, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "the overall survival rate of each group", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01914289"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Eastern Hepatobiliary Surgery Hospital", 
            "investigator_full_name": "ShenFeng", 
            "investigator_title": "director of department of special treatment", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Eastern Hepatobiliary Surgery Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eastern Hepatobiliary Surgery Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}